Literature DB >> 2261596

Carbohydrate-derivatized immunoconjugate of the anti-(carcinoembryonic antigen) monoclonal antibody C46: immunohistological reactivity and pharmacokinetic comparison with a randomly derivatized C46 immunoconjugate.

M J Rosenstraus1, W L Davis, A D Lopes, C J D'Aleo, S C Gilman.   

Abstract

In this study, a site-specific glycyl-tyrosyl-(N-epsilon-diethylenetriaminepentaacetic acid)-lysine (GYK-DTPA) immunoconjugate of the anti-carcinoembryonic antigen monoclonal antibody C46 (C46-GYK-DTPA) was characterized by immunohistological and immunofluorescence methods for reactivity with normal and neoplastic human tissues. In addition, pharmacokinetic studies assessed the ability of C46-GYK-DTPA labeled with 111In to localize to and image human tumor xenografts in nude mice. The native antibody and the site-specific immunoconjugate exhibited similar patterns of reactivity with normal human tissues. C46 did not bind to the surface of normal human granulocytes, which indicates lack of reactivity with normal cross-reacting antigen. C46-GYK-DTPA reacted with 100% of the colon, breast and renal carcinomas examined and with two of three lung carcinomas, but did not react with any sarcomas, melanomas or lymphomas examined. Intravenously administered C46-GYK-DTPA-111In rapidly localized to and imaged LS174T human colon adenocarcinoma xenografts in nude mice, reaching maximal levels of about 25% of injected dose/g tumor within 1 day. No unusual localization to any non-tumor tissue or organ was seen; the level of radioactivity in the normal tissues and organs was at or below that in the blood. The accessible binding sites in 1 g tumors appeared to be saturated at an antibody dose between 100 micrograms and 1000 micrograms/mouse. Further, in a direct in vivo comparison, the site-specific conjugate C46-GYK-DTPA had more favorable pharmacokinetics and better tumor localization than a randomly derivatized C46 immunoconjugate (C46-DTPA). These findings suggest that the site-specific immunoconjugate C46-GYK-DTPA may be useful in the diagnosis and therapy of colon cancer and other adenocarcinomas expressing carcinoembryonic antigen.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2261596     DOI: 10.1007/bf01741702

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  16 in total

1.  Radioactive labeling of antibody: a simple and efficient method.

Authors:  D J Hnatowich; W W Layne; R L Childs; D Lanteigne; M A Davis; T W Griffin; P W Doherty
Journal:  Science       Date:  1983-05-06       Impact factor: 47.728

2.  Monoclonal antibody against carcinoembryonic antigen (CEA) identifies two new forms of crossreacting antigens of molecular weight 90,000 and 160,000 in normal granulocytes.

Authors:  M Audette; F Buchegger; M Schreyer; J P Mach
Journal:  Mol Immunol       Date:  1987-11       Impact factor: 4.407

3.  Radioimmunoscintigraphy with 111In labelled monoclonal antibody fragments (F(ab')2 BW 431/31) against CEA: radiolabelling, antibody kinetics and distribution, findings in tumour and non-tumour patients.

Authors:  R Bares; J Fass; S Truong; U Buell; V Schumpelick
Journal:  Nucl Med Commun       Date:  1989-09       Impact factor: 1.690

4.  Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy.

Authors:  J P Mach; F Buchegger; M Forni; J Ritschard; C Berche; J D Lumbroso; M Schreyer; C Girardet; R S Accolla; S Carrel
Journal:  Immunol Today       Date:  1981-12

5.  99Tcm-labelled anti-CEA monoclonal antibody for tumour immunoscintigraphy: first clinical results.

Authors:  R P Baum; A Hertel; M Lorenz; A Schwarz; A Encke; G Hör
Journal:  Nucl Med Commun       Date:  1989-05       Impact factor: 1.690

6.  Circulating immune complexes in cancer patients receiving goat radiolocalizing antibodies to carcinoembryonic antigen.

Authors:  F J Primus; S J Bennett; E E Kim; F H DeLand; M C Zahn; D M Goldenberg
Journal:  Cancer Res       Date:  1980-03       Impact factor: 12.701

7.  The preparation of DTPA-coupled antibodies radiolabeled with metallic radionuclides: an improved method.

Authors:  D J Hnatowich; R L Childs; D Lanteigne; A Najafi
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

8.  A prospective study of the use of 111In-labelled monoclonal antibody against carcino-embryonic antigen in colorectal cancer and of some biological factors affecting its uptake.

Authors:  M Granowska; J R Jass; K E Britton; J M Northover
Journal:  Int J Colorectal Dis       Date:  1989       Impact factor: 2.571

9.  Immunoscintigraphy of adenocarcinomas by means of radiolabeled F(ab')2 fragments of an anti-carcinoembryonic antigen monoclonal antibody: a multicenter study.

Authors:  A G Siccardi; G L Buraggi; L Callegaro; A C Colella; P G De Filippi; G Galli; G Mariani; R Masi; R Palumbo; P Riva
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

10.  DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES.

Authors:  P GOLD; S O FREEDMAN
Journal:  J Exp Med       Date:  1965-03-01       Impact factor: 14.307

View more
  1 in total

Review 1.  Site-Specifically Labeled Immunoconjugates for Molecular Imaging--Part 1: Cysteine Residues and Glycans.

Authors:  Pierre Adumeau; Sai Kiran Sharma; Colleen Brent; Brian M Zeglis
Journal:  Mol Imaging Biol       Date:  2016-02       Impact factor: 3.488

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.